131266Development of a novel VLP based vaccine for malariaClosedFeasibility StudiesInnovate UKMalaria remains a major cause of death, particularly in many developing countries. Currently no vaccine is commercially available and existing pharmaceuticals are becoming less and less effective due to parasitic resistance, while insecticide resistance in diminishing the utility of that intervention. Therefore, we propose to develop an new and potent vaccine using a delivery system developed by iQur Ltd and malaria antigens under development by the Jenner Institute at Oxford University. In this feasibility study, we will prepare a virus like particle (VLP), which will carry the malaria target antigens, and test these vaccines for safety, immunogenicity and efficacy in mice. VLPs are well accepted as a safe delivery system and give rise to strong immune responses. If this study is successful, we will then initiate a clinical development programme which will bring this vaccine to market